What's New:

1. Direct Thrombin Inhibitors

January 23, 2012

Reversal of Direct Thrombin Inhibitors (i.e. Dabigatran / Pradaxa) and Direct Factor Xa Inhibitors (i.e. Rivaroxaban / Xarelto).

At this time, there is insufficient evidence available to allow the National Advisory Committee on Blood and Blood Products (NAC) to develop a recommendation for use of prothrombin complex concentrates, FEIBA or recombinant Factor VIIa in the reversal of Direct Thrombin Inhibitors or Direct Factor Xa Inhibitors.

2. Massive Transfusion Consensus Conference - June 2011

Update - January 23, 2012 - Critical Care - full article available:
Canadian National Advisory Committee on Blood and Blood Products; Massive Transfusion Consensus Conference, 2011: Report of the Panel

A summary of the conference proceedings is also being prepared for publication.

Conference Presentations
Conference Questions, Panelists and Presenters

3. Prothrombin Complex Concentrate Recommendations

To access the most recent recommendations, Click here.

4. National Plan for the Management of Shortages of Labile Blood Components

Click here to access the Plan.

The Blood Shortage Working Group (BSWG) maintains the Plan on behalf of the National Advisory Committee on Blood and Blood Products (NAC).